Nicolle M Gatto

List of Publications by Year
in descending order

22 papers	851 citations	686830 13 h-index	713013 21 g-index
25 all docs	25 docs citations	25 times ranked	1051 citing authors

#	Article	IF	Citations
1	The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework. Clinical Pharmacology and Therapeutics, 2022, 111, 122-134.	2.3	25
2	Categorization of <scp>COVID</scp>‐19 severity to determine mortality risk. Pharmacoepidemiology and Drug Safety, 2022, 31, 721-728.	0.9	10
3	Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study. Clinical and Translational Science, 2022, 15, 1990-1998.	1.5	4
4	Real‐World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID‐19. Clinical Pharmacology and Therapeutics, 2021, 109, 816-828.	2.3	29
5	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLoS ONE, 2021, 16, e0248128.	1.1	9
6	Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. Journal of Comparative Effectiveness Research, 2021, 10, 711-731.	0.6	32
7	Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME). Contemporary Clinical Trials Communications, 2020, 18, 100427.	0.5	5
8	Association of Azithromycin Use With Cardiovascular Mortality. JAMA Network Open, 2020, 3, e208199.	2.8	30
9	Lung Cancer‐Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results. Diabetes Care, 2019, 42, 1708-1715.	4.3	4
10	A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real‐World Evidence for Regulatory Decisions. Clinical Pharmacology and Therapeutics, 2019, 106, 103-115.	2.3	36
11	Implications of product withdrawal on a post-approval pragmatic trial: The VOLUME study experience. Contemporary Clinical Trials Communications, 2019, 16, 100477.	0.5	1
12	Heeding the call for less casual causal inferences: the utility of realized (quantitative) causal effects. Annals of Epidemiology, 2017, 27, 402-405.	0.9	6
13	Methodological comparison of marginal structural model, time‐varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 114-121.	0.9	24
14	Causal identification: a charge of epidemiology in danger of marginalization. Annals of Epidemiology, 2016, 26, 669-673.	0.9	35
15	Is the "well-defined intervention assumption" politically conservative?. Social Science and Medicine, 2016, 166, 254-257.	1.8	42
16	Toward a Clarification of the Taxonomy of "Bias" in Epidemiology Textbooks. Epidemiology, 2015, 26, 216-222.	1.2	21
17	An Organizational Schema for Epidemiologic Causal Effects. Epidemiology, 2014, 25, 88-97.	1.2	13
18	The authors respond. Epidemiology, 2014, 25, 619-620.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Extending the sufficient component cause model to describe the Stable Unit Treatment Value Assumption (SUTVA). Epidemiologic Perspectives and Innovations, 2012, 9, 3.	7.0	27
20	Redundant causation from a sufficient cause perspective. Epidemiologic Perspectives and Innovations, 2010, 7, 5.	7.0	22
21	Author's response to Poole, C. Commentary: How Many Are Affected? A Real Limit of Epidemiology. Epidemiologic Perspectives and Innovations, 2010, 7, 7.	7.0	1
22	Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. Journal of the National Cancer Institute, 2003, 95, 230-236.	3.0	468